Stocklytics Platform
Asset logo for symbol SLN
Silence Therapeutics plc
SLN52
$5.61arrow_drop_down4.91%-$0.29
Asset logo for symbol SLN
SLN52

$5.61

arrow_drop_down4.91%

Income Statement (SLN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$21.55M-$17.25M-$4.15M-$15.02M-$10.65M
EBITDA-$21.44M-$17.13M-$4.03M-$14.90M-$10.52M
gross Profit-$1.63M-$2.04M$10.19M$753.00K$1.19M
NET Income-$27.01M-$15.56M-$1.87M-$14.41M-$8.25M
total Revenue$1.14M$598.00K$12.40M$2.09M$2.79M

Balance Sheet (SLN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$61.81M-$109.29M-$112.77M-$53.75M-$58.49M
stockholders Equity$94.51M$112.50M$123.90M$17.05M$19.99M
total Assets$169.38M$188.63M$194.37M$93.82M$97.94M
total Debt$139.00K$184.00K$277.00K$272.00K$315.00K
total Liabilities$74.86M$76.12M$70.47M$76.77M$77.94M

Cash Flow (SLN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$5.96M$847.00K$105.56M$9.92M$12.03M
free Cash Flow-$19.70M-$4.88M-$7.49M-$11.86M-$4.89M
investing Cash Flow-----
operating Cash Flow-$19.65M-$4.81M-$7.49M-$11.86M-$4.87M

Silence Therapeutics plc (SLN) Financials

Silence Therapeutics plc (SLN) is a biotechnology company specializing in the development and commercialization of RNA-based therapeutics. The company's financials provide insight into its performance and financial health. The income statement shows the company's revenue and expenses over a specific period. It reveals Silence Therapeutics' net income from stockholders, gross profit, and total revenue. These figures reflect the company's profitability and revenue generation capabilities.
The balance sheet provides a snapshot of Silence Therapeutics' financial position at a specific point in time. It includes the company's total assets, total liabilities, and stockholders' equity. This information helps assess the company's financial stability and its ability to meet its financial obligations. Silence Therapeutics' cash equivalents and net debt also provide insights into its liquidity and leverage.
Cash flow statements detail the sources and uses of cash for Silence Therapeutics. The operating cash flow shows the cash generated from the company's core operations, while the investing cash flow and financing cash flow account for cash flows related to investments and financing activities. Silence Therapeutics' free cash flow is a measure of its ability to generate cash after accounting for capital expenditures.
As a publicly traded company, Silence Therapeutics' financials are crucial for investors and stakeholders to evaluate its financial performance and make informed decisions. These financial statements offer valuable insights into the company's revenue, expenses, profitability, liquidity, and financial health.
add Silence Therapeutics plc to watchlist

Keep an eye on Silence Therapeutics plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level